Clinical effects and toxicity of interleukin-2 in patients with cancer

摘要: Interleukin-2 (IL-2) is a 15,000 dalton glycoprotein produced naturally by human T-cells during an immune response. IL-2 has been demonstrated to have substantial activity alone or in combination with the adoptive transfer of lymphokine-activated killer cells murine tumor models. derived from both natural (Jurkat T-cell tumor) and recombinant (Escherichia coli) sources studied Phase I protocols designed evaluate toxicity patients variety solid tumors ascertain improvement clinical parameters immunologic status. A total 16 (7 acquired deficiency syndrome [AIDS] 9 non-AIDS malignancies) were treated Jurkat IL-2. The maximum dose (1.3 X 10(5) U/kg) was limited only supply this reagent. 25 (RIL-2) alone. Dose-limiting manifested marked malaise weight gain achieved doses RIL-2 10(6) U/kg as single bolus 3000 U/kg/hr. could be administered intraperitoneally similar toxicity. Minimal renal hepatic demonstrated. Hematologic mild anemia (25/25), thrombocytopenia (10/25), reversible eosinophilia (15/25). Pronounced greater than 2 kg (16/25) occurred most patients, primarily those who received cumulative 1-3 amounted much 10% 20% pretreatment over 3 weeks treatment our ability give higher doses. Two partial responses (greater 50% decrease cross sectional diameters) seen two melanoma metastatic lung.